Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.51 |
| ▸ | MTOR | P42345 | 8/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.44 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12987134 | 1.00 | PIK3CA (0.51) | PIK3CAMTORPIK3R1CYP3A4RPTOR | |
| Trifluoroacetic Acid SCHEMBL15769309 | 0.95 | PIK3CA (0.46) | PIK3CAMTORPIK3R1 | |
| Trifluoroacetic Acid SCHEMBL15769310 | 0.95 | PIK3CA (0.46) | PIK3CAMTORPIK3R1 | |
| SCHEMBL12986891 | 0.92 | PIK3CA (0.51) | PIK3CAMTORCYP3A4RPTORMLST8 | |
| SCHEMBL15769378 | 0.92 | MTOR (0.53) | PIK3CAMTORPIK3R1 | |
| SCHEMBL12989060 | 0.92 | MTOR (0.53) | PIK3CAMTORPIK3R1 | |
| SCHEMBL15769559 | 0.92 | PIK3CA (0.49) | PIK3CAMTORPIK3R1CYP3A4RPTOR | |
| SCHEMBL13195159 | 0.92 | PIK3CA (0.49) | PIK3CAMTORPIK3R1CYP3A4RPTOR | |
| SCHEMBL12988381 | 0.91 | PIK3CA (0.54) | PIK3CAMTORPIK3R1 | |
| SCHEMBL12988377 | 0.91 | PIK3CA (0.54) | PIK3CAMTORPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163023-A1 | DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-06-12 | — | — | US | claimed |
| EP-2694511-A1 | DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | Cellzome Limited (GB) | 2014-02-12 | — | — | EP | claimed |
| WO-2012136622-A1 | DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-11 | — | — | WO | claimed |
| US-20140163023-A1 | DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | CELLZOME LIMITED (GB) | 2014-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163023-A1 | DIHYDROPYRROLO PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | MTOR, RICTOR, RPTOR | PIK3CA 34/4885MTOR 1/4885PIK3R1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.